Biotech Values

[rfj1862]

Consensus seems to be around $3-4B *after* positive NASH results. This is also consistent with analyst targets, more or less.

Right now VKTX is being valued similarly to AKRO, which has a somewhat junky injectable that had okay results in a Phase 2 trial and has no other viable products.

If NASH is positive, oral GLP-1/GIP is positive, and the X-ALD program is also positive, who knows?